Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ACRS declined for three days, in of 311 cases, the price declined further within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 60 cases where ACRS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The 10-day moving average for ACRS crossed bearishly below the 50-day moving average on May 16, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Aroon Indicator for ACRS entered a downward trend on May 24, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on May 23, 2023. You may want to consider a long position or call options on ACRS as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ACRS just turned positive on May 23, 2023. Looking at past instances where ACRS's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRS advanced for three days, in of 275 cases, the price rose further within the following month. The odds of a continued upward trend are .
ACRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.313) is normal, around the industry mean (25.170). P/E Ratio (0.000) is within average values for comparable stocks, (143.128). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.619). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (17.889) is also within normal values, averaging (52.265).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ACRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of novel dermatological therapies
A.I.dvisor indicates that over the last year, ACRS has been loosely correlated with STRRP. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRS jumps, then STRRP could also see price increases.
|STRRP - ACRS|
|UFPT - ACRS|
|PACB - ACRS|
|DXCM - ACRS|
|AZTA - ACRS|